We are live on ! Find out more
SPRO icon

Spero Therapeutics

80 hedge funds and large institutions have $159M invested in Spero Therapeutics in 2020 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 34 increasing their positions, 12 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 8

183% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 12

71% more capital invested

Capital invested by funds: $93.2M → $159M (+$66.1M)

33% more funds holding

Funds holding: 6080 (+20)

0.44% more ownership

Funds ownership: 56.73%57.17% (+0.44%)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

Holders
80
Holders Change
+20
Holders Change %
+33.33%
% of All Funds
1.64%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
28
Increased
34
Reduced
12
Closed
8
Calls
$19K
Puts
Net Calls
+$19K
Net Calls Change
+$19K

SPRO Hedge Fund Activity: Q2 2020 in Review

80 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Spero Therapeutics (SPRO) for Q2 2020, worth a combined $159M — up 71% from $93.2M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new SPRO positions and 8 closed out — a net gain of 20 holders — while 34 added to existing stakes and 12 trimmed.

The largest buyer was Aquilo Capital Management, adding an estimated $1.4M. The largest seller was VR Adviser, exiting entirely with an estimated $3.83M sold.

  • 80 institutional investors held Spero Therapeutics (SPRO) as of Q2 2020, up from 60 in Q1 2020.
  • Funds reported $159M of Spero Therapeutics stock for Q2 2020, up 71% quarter-over-quarter.
  • 28 funds opened new Spero Therapeutics positions in Q2 2020 and 8 closed out, a net change of +20 holders.
  • The largest Spero Therapeutics buyer in Q2 2020 was Aquilo Capital Management, an estimated $1.4M added.
  • The largest Spero Therapeutics seller in Q2 2020 was VR Adviser, an estimated $3.83M sold.

Based on aggregated 13F filings for Q2 2020.